ForSight Robotics, an Israel-based company developing robotic technology for ophthalmic surgery, has completed a Series B financing round that brought in $125 million. The round was led by Eclipse Ventures, a venture capital firm with a focus on industrial and healthcare technology. According to reporting from The Robot Report, the financing also included participation from an undisclosed strategic investor, as well as board member Fred Moll, who is widely recognized as a pioneer in the surgical robotics field. Existing investors, including The Adani Group and Reiya Ventures, also joined the round.
The Series B brings ForSight Robotics' total funding to $195 million. The company has stated that it intends to use the capital to accelerate the next phase of growth for its Oryom platform, which it describes as the world's first robotic surgery platform designed for cataract procedures and other widespread eye diseases. The platform relies on AI-based algorithms, advanced computer vision, and miniaturized mechanics to assist surgeons in performing delicate ophthalmic operations.
The funding announcement was made in June 2025, according to The Robot Report's coverage. The exact day of the announcement is not specified in the source material, so month-level precision is appropriate here.
ForSight Robotics was born out of Israel's Technion Institute, where co-founders Moshe Shoham, Nathan, and Daniel Glozman combined their expertise in medical engineering, research and development, and commercialization. Shoham is a Technion professor and a pioneer behind multiple robotics companies, including Mazor Robotics, which was acquired by Medtronic for $1.6 billion. Shoham's previous students have gone on to lead Medtronic's robotics division and to build multi-billion-dollar exits, according to reporting cited by The Robot Report.
The company's advisory structure includes both Moll and Shoham, who are sometimes referred to as "the godfathers of surgical robotics." They now advise ForSight strategically, according to the source material.
The funding round is notable not just for its size but for the caliber of investors and advisors involved. Moll's participation is particularly significant given his role as co-founder of Intuitive Surgical, the company behind the da Vinci surgical system, which has become a standard in soft tissue robotic surgery worldwide. His involvement signals a level of confidence in ForSight's approach to ophthalmic robotics.
Why it matters for European robot service
The European robotics market has been watching the ophthalmic surgery space with growing interest, and ForSight's Series B is a signal that this niche is attracting serious capital. The company's focus on cataract surgery is particularly relevant for Europe, where aging populations are driving increased demand for ophthalmic procedures.
Cataract surgery is one of the most commonly performed surgical procedures globally, and Europe is no exception. The procedure involves operating within extremely small spaces in the eye, requiring steady hands and dexterous control. ForSight says its Oryom platform is designed specifically to handle the complexity and consistency of ophthalmic procedures, using AI-based algorithms, computer vision, and micromechanics to enhance surgical precision and reduce the physical strain on surgeons.
The company's stated rationale for developing this technology is twofold: anticipating rising demand for ophthalmic surgery while addressing a shortage of surgeons. This is a challenge that resonates across European healthcare systems, where surgical workforce shortages are a persistent concern. If robotic platforms can help existing surgeons perform more procedures with less physical strain, or enable less-experienced surgeons to achieve higher levels of precision, the potential impact on patient access to care could be substantial.
For European robot service providers and integrators, the emergence of a dedicated ophthalmic robotic platform represents both an opportunity and a consideration. The technology is still in its growth phase, and ForSight has not disclosed specific commercialization timelines for the European market. What is known is that the company plans to use its new funding to accelerate the next growth phase for the Oryom platform, which suggests that regulatory pathways, clinical trials, and market entry strategies are likely priorities.
The broader context is also worth noting. Other companies are targeting untapped niches in robotics. In July 2025, Olympus revealed plans to co-found a new company with Revival Healthcare Capital to create a robotic system focused on gastrointestinal treatments. In June 2025, ForSight Robotics said it is developing the first robotic surgery platform for cataracts and other eye diseases. These developments indicate a trend toward specialization in surgical robotics, moving beyond the general-purpose systems that have dominated the market.
For European healthcare providers, the potential arrival of ophthalmic robotic systems raises questions about training, integration with existing surgical workflows, and the economics of adopting such technology. The source material does not provide specific details on these aspects, so it is important to note that these considerations remain open questions rather than answered ones.
The involvement of advisors like Moll and Shoham adds credibility to ForSight's technical approach. Moll's track record with Intuitive Surgical demonstrates that robotic surgery platforms can achieve widespread adoption when they deliver clear clinical benefits. Shoham's experience with Mazor Robotics shows a path from academic research to commercial success, including a significant acquisition by a major medical device company.
For European robot service companies, the development of ophthalmic robotics could create new service opportunities. Robotic systems require installation, maintenance, training, and ongoing support. If ForSight's Oryom platform enters the European market, there will likely be a need for local service partners who understand both the technology and the regulatory environment. However, the source material does not disclose any specific plans for European distribution or service partnerships, so this remains speculative.
The timing of the funding round is also relevant. The source material indicates that the announcement was made in June 2025, with The Robot Report's coverage published around that time. The broader market context includes other significant funding rounds in the medical robotics space, such as OrganOx raising $142 million for organ transplant technology, SetPoint Medical raising $140 million for neuromodulation commercialization, and Kestra Medical Technologies pricing a $138 million offering. These figures suggest that investors are actively funding medical technology innovations, and ForSight's $125 million round is part of this trend.
What buyers and operators should know
For healthcare providers, hospital administrators, and surgical teams considering ophthalmic robotic technology, the ForSight funding announcement provides some clarity but also leaves many questions unanswered.
What is known is that ForSight Robotics has now raised a total of $195 million, with the Series B round led by Eclipse Ventures. The company's Oryom platform is described as the world's first robotic surgery platform for cataracts and widespread eye diseases. The platform uses AI-based algorithms, advanced computer vision, and miniaturized mechanics to support surgical precision.
The company was founded out of Israel's Technion Institute, with co-founders who have deep expertise in medical engineering and robotics. Shoham's track record includes founding multiple robotics companies, including Mazor, which was acquired by Medtronic for $1.6 billion. This background suggests a level of technical competence and commercial awareness that buyers may find reassuring.
However, several important details are not disclosed in the source material. The specific regulatory status of the Oryom platform is not stated. Whether the platform has received CE marking for European use, or FDA clearance for the U.S. market, is not mentioned. The source material does not indicate whether the platform has been used in clinical trials, and if so, what the results were. These are critical considerations for any healthcare provider evaluating new surgical technology.
The source material also does not disclose pricing information for the Oryom platform. There are no details on the cost of the system, the cost of consumables or disposables, or the total cost of ownership over time. Buyers should be aware that robotic surgical systems typically involve significant upfront capital expenditures as well as ongoing costs for maintenance, service, and training. None of these figures are available in the source material.
Similarly, there is no information on service and support infrastructure. The source material does not mention service response times, spare part availability, or maintenance contracts. For European buyers, the availability of local service support would be a key consideration, but this information is not disclosed.
The source material does indicate that ForSight anticipates rising demand for ophthalmic surgery and a shortage of surgeons. This suggests that the company sees its technology as addressing a workforce challenge, not just a clinical one. For hospital administrators, this framing may be relevant when considering the business case for adopting robotic ophthalmic surgery. If the technology can enable more procedures to be performed with the same or fewer surgeons, the return on investment could be compelling. However, the source material does not provide specific data on procedure times, patient outcomes, or surgeon productivity with the Oryom platform.
The involvement of Fred Moll and Moshe Shoham as strategic advisors is notable. Moll's experience with Intuitive Surgical demonstrates that robotic surgery can become a standard of care when the technology delivers measurable benefits. Shoham's experience with Mazor Robotics shows a path from academic research to commercial success. These advisors' involvement may provide some confidence in the technology's potential, but it is not a substitute for clinical evidence.
Buyers should also consider the competitive landscape. The source material mentions that other companies are targeting untapped niches in robotics, such as Olympus's plans for a gastrointestinal robotic system. In the ophthalmic space specifically, ForSight claims to be first, but the source material does not provide a comprehensive overview of competitors or alternative technologies. Buyers should conduct their own due diligence to understand the full range of options available.
The source material does not disclose the timeline for commercial availability of the Oryom platform. It is not clear when the platform might be available for purchase in Europe, what regulatory approvals are pending, or what the company's roadmap looks like. Buyers interested in this technology should monitor ForSight's announcements for updates on regulatory status, clinical data, and commercialization plans.
It is also worth noting that the source material does not provide information on the company's manufacturing capacity, supply chain, or quality management systems. For a medical device company, these factors are critical to ensuring reliable product availability and consistent quality. None of this information is disclosed.
For operators and surgical teams, the key question is how the Oryom platform would integrate into existing workflows. The source material describes the platform as using AI-based algorithms, advanced computer vision, and miniaturized mechanics, but it does not provide details on the user interface, training requirements, or the learning curve for surgeons. These are practical considerations that would need to be addressed before adoption.
The source material also does not address data security or interoperability with existing hospital information systems. As robotic platforms become more connected, these considerations become increasingly important. Buyers should ask about data handling practices, cybersecurity measures, and compatibility with electronic health record systems.
In summary, the ForSight Robotics Series B funding round is a significant development in the ophthalmic robotic surgery space. The company has raised substantial capital, attracted notable investors and advisors, and is developing a platform that could address real clinical needs. However, for European buyers and operators, many practical questions remain unanswered. The source material provides a foundation of information about the company and its technology, but it does not address regulatory status, pricing, service infrastructure, or clinical evidence. Buyers should approach this technology with informed caution, seeking additional information from the company and monitoring for future announcements.
As with any emerging medical technology, the path from funding to clinical adoption is long and uncertain. The $125 million Series B gives ForSight the resources to pursue its vision, but it does not guarantee commercial success. European buyers and operators should watch this space closely, as ophthalmic robotics could eventually become a meaningful option for addressing the growing demand for cataract surgery and other eye procedures.
Sources
Published by Vigla Media OÜ (Estonia).